Ozempic tops list of 15 drugs whose negotiated prices will take effect in 2027

Delaware judge rules against AstraZeneca, focusing attention on upcoming cases

Plus: June PDUFA date for Daiichi-Merck ADC, and updates from Lyndra, ImpriMed, Mundipharma and Novamab 

Case aims at Supreme Court’s skepticism about executive power

AZ is moving Farxiga combinations into Phase III testing that it believes can help reach underserved patient subsets 

Arguments for aggregating drugs could apply to Novo Nordisk lawsuit

A fifth company, Novo Nordisk ‘exploring options’

Travere aims to establish Filspari as standard of care in IgA nephropathy, even with the drug’s liver toxicity monitoring and restricted label

Weeks after AZ buys competitor, newly listed biotech exceeds expectations as it preps pivotal studies of ALDOS inhibitor for hypertension

Farxiga’s 56% growth shows how settings outside diabetes are recharging sales for SGLT2 therapies